Virus Powered Immunotherapies against Solid Tumors - Corporate Presentation 29 June 2021
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Virus Powered Immunotherapies against Solid Tumors Corporate Presentation 29 June 2021
Disclaimer
This presentation contains forward-looking statements, which are subject to numerous risks and uncertainties, which
could cause actual results to differ materially from those anticipated. There can be no guarantee that (i) the results of
pre-clinical work and prior clinical trials will be predictive of the results of the clinical trials currently under way, (ii)
regulatory authorities will agree with the Company’s further development plans for its therapies, or (iii) the Company will
find development and commercialization partners for its therapies in a timely manner and on satisfactory terms and
conditions, if at all. The occurrence of any of these risks could have a significant negative outcome for the Company’s
activities, perspectives, financial situation, results and development.
For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition,
performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk
Factors (“Facteurs de Risques”) section of the Universal Registration Document, available on the AMF website
(http://www.amf-france.org) or on Transgene’s website (www.transgene.fr). Forward-looking statements speak only as
of the date on which they are made and Transgene undertakes no obligation to update these forward-looking
statements, even if new information becomes available in the future.
2
A World-Leader in Virus Powered Immunotherapies
Click to edit Master title style
Ability to Customised Demonstrated Integrated Ability Attractive Transgene’s
select and and off-the- induction GMP to conduct technologies technologies
engineer shelf products of immune manufacturing clinical could deliver
Collaborations
various response, capacity for studies until with NEC, a game
products, including rapid delivery POC Merck/Pfizer,
Solid safety of pilot scale changing
thanks to our tumor-specific AstraZeneca,
experience in track record T cell response, batches approach
viral vectors, associated with to the
Mayo Clinic,
protein anti-tumor
Institut Curie
treatment of
engineering, activity solid tumors
and tumor
antigens
Right virus Right payload Right indication Right patient population
3
Our Expertise Translates into Two Unique Technology Platforms
Able
Click toto
edittarget multiple
Master title style solid tumors
THERAPEUTIC VACCINE (MVA)
Patient specific antigens selected to generate the
optimal immune response
Vaccinia Immune T cell activation through multi-mechanisms
vector • Priming of innate
and adaptive TUMOR CELL Enlarged
immunity immune
DEATH response &
• Demonstrated
safety
repertoire
ONCOLYTIC VIRUS (VVcopTK-RR-)
Direct and specific tumor oncolysis
Immune cells activation through multi-mechanisms
Additional activity generated by therapeutic payloads
4
Multiple Opportunities to Transform Solid Tumor Therapy
Click to edit Master title
Product style
Indication Target/Transgene Design Preclinical Phase I Phase II Next step
THERAPEUTIC VACCINES
Ovarian cancer 1st data 4Q 2021
TG4050 30 neoantigens
Head and neck cancers 1st data 4Q 2021
Anogenital HPV+ Interim analysis
TG4001 cancers
HPV 16 E6 – E7
around end 2022
ONCOLYTIC VIRUSES (OV)
Gastro-intestinal Last patient enrolled
cancers (IV*) 5-FU Q4 2021
TG6002 chemotherapy 1st safety/translational
Colorectal cancer (IHA*) 2H 2021
BT-001 Solid tumors
Anti-CTLA4 1st Phase I data
+ GM-CSF 1H 2022
Best candidates
OVs Solid tumors Undisclosed selection to enter into
clinical dev.
Potential option
5 OVs Undisclosed
exercise
5
* IV: intravenous administration, IHA: intrahepatic artery administration
Individualized
Neoantigen Vaccine
Taking the Treatment of Each Patient’s Tumor
to a New Level
Cutting-Edge Approach
one patient • one genome • one vaccine
myvac® | Taking the Treatment of Each Patient’s Tumor to a New Level
by
Clickcapitalizing onstyle
to edit Master title multiple cutting-edge technologies
Demonstrated capability of
MVA to induce antigen
specific immune response –
well-established safety profile 2 ongoing
clinical trials TG4050:
Patient specific neoantigens 1st candidate based on
are highly immunogenic – the myvac® platform
different from self and specific
to each patient Transgene has
Click here
in-house expertise (VacDesignR™)
to optimize insertion of NEC covers 50%
Improved genetic engineering neoantigens
design for the myvac® MVA in the myvac® MVA backbone
of the development
vector cost of TG4050
NEC’s AI uses multiple
biological and physico-
chemical parameters to
identify most immunogenic
neoantigens*
*Source: Mallone et al., “Performance of
neoantigen prediction for the design of TG4050, a
patient specific neoantigen cancer vaccine”, AACR, 7
June 2020, Poster presentation
Producing TG4050, First Clinical Batches of the Individualized Immunotherapy Already Released
Click to edit Master title style
GMP facility Manufacturing process Current lead-time
in place in place and being from tumor biopsy to tailored
progressively vaccine shipment in line with
automated objectives
8
TG4050 | First Individualized Vaccine Based on the myvac® Technology
2Click
ongoing clinical
to edit Master trials
title style
Moderately mutated
myvac® tumors
MVA Ovarian and Head
Established safety & Neck cancers
and
Limited efficacy of
immunogenicity
checkpoint blockers
DESIGNED TG4050 (low/medium TMB*)
TO TREAT
PATIENTS INDIVIDUALIZED CANCER
WITH VACCINE
ESTABLISHED
Selected Patients in clinical remission
DISEASE patients with undetectable residual
neoantigens disease
Highly immunogenic Allows the use of TG4050
Optimized gene editing technologies as monotherapy
9
*TMB: tumor mutation burden
TG4050 | Ovarian Cancer Trial after Surgery and Adjuvant Chemotherapy
Phase I trial
Click to edit in title
Master 13style
patients (NCT03839524)
First patient Surgery Asymptomatic relapse
enrolled in
January 2020 Adjuvant Clinical remission TG4050 (single agent) treatment
Platinum chemotherapy | TG4050 production
Complete response
ANALYSES INCLUDE LEAD INVESTIGATOR: Matthew S. Block,
MD, PhD, Mayo Clinic (Rochester)
characterization of T-cell immune response
change in tumor micro-environment
clinical outcome
First clinical data in 4Q 2021
10TG4050 | HPV-Negative Head and Neck Cancer Trial after Surgery and Adjuvant Therapy
Randomized
Click to edit MasterPhase I trial in 30 patients (NCT04183166)
title style
Arm
First patient Surgery Complete
A Recurrence
response TG4050
enrolled in single agent
Adjuvant Chemo/radio therapy TG4050 + SOC
January 2020 | TG4050 production (incl. checkpoint blockers)
Patient
monitoring
Arm Recurrence
B
ANALYSES INCLUDE LEAD INVESTIGATOR: Pr. Christian Ottensmeier,
Clatterbridge cancer care center, Liverpool
characterization of T-cell immune response
change in tumor micro-environment
clinical outcome
First clinical data in 4Q 2021
11TG4050 | Next Milestones
Ongoing
Click to edit trials – Could
Master title style treat patients with an established disease
Our strategy is to: Clinical program backed by extensive genomic First clinical
and immunologic translational research data from
Demonstrate vaccine activity at biological and clinical project in collaboration with academic and private ongoing trials
stages in patients with minimal disease (allowing the top-level players (Institut Curie, HalioDx, expected
use of vaccine in monotherapy) BostonGene, Mayo Clinic, University of Liverpool).
The programs aims at:
4Q 2021
Characterize vaccine biology and mechanism Will serve as
comprehensively and validate our design Accelerating future clinical development
basis for
Potentially identifying particular subpopulation partnering
Based on vaccine biology, determine the most relevant with a differentiated response
discussions
clinical positioning including potential combination and
target populations
TG4050 monotherapy has potential to expand to other solid tumors
in patients with minimal residual disease
12TG4001 Potential to Transform the Treatment of Anogenital HPV Positive Solid Tumors Interim analysis expected around the end of 2022
TG4001 | Virus Powered Candidate Vaccine
Click to edit Master title style
The right indication
The right virus
anogenital
MVA
HPV16-positive
cancers
Click here
OPTIMIZED TREATMENT
FOR HPV-POSITIVE
TUMORS The right
The right HPV antigens patient population
E6 and E7 Patients without liver
metastasis
14TG4001 | Phase Ib/II Data of TG4001 with Avelumab Presented at SITC 2020
Promising results,
Click to edit Master particularly in patients without liver metastasis (NCT03260023)
title style
Collaboration
34 heavily pretreated patients with
with metastatic HPV16+ cancer
(oropharyngeal, anogenital)
Identified target population: Compares
patients without favorably to
liver metastasis (n=23) ICIs in
monotherapy
34.8%
vs patients with liver metastasis (n=11)
5.6 and
vs 0%
MONTHS competitive
vs 1.4 month landscape
Source: Le Tourneau et al.
“TG4001 (Tipapkinogene
sovacivec) and avelumab for
1 COMPLETE
RESPONSE
Patient with anal cancer and peritoneal 7 PARTIAL
RESPONSES
recurrent/metastatic (R/M)
Human Papilloma Virus (HPV)-
16+ cancers: clinical efficacy and
immunogenicity.” 2020 SITC
Annual Meeting, 9-11
extension that all disappeared – still November 2020, Poster
followed in the trial presentation
15
ORR: objective response rate (RECIST 1.1); mPFS: median progression-free survivalExpanded Trial Focuses on Patient Population that Derived Improved Clinical Benefit in Phase Ib/II
Click to edit Master title style
Patients with HPV16-positive anogenital cancer
including cervical, vulvar, vaginal, penile and anal cancers
With recurrent/metastatic disease
Treated in first line or in second line (with a maximum of one prior systemic
chemotherapy versus two allowed in Phase Ib/II trial)
Without previous exposure to cancer immunotherapy
Without liver metastasis at baseline
Including all levels of PD-L1 expression
16TG4001 | Randomized Controlled Phase II Trial Supported by Clinicians
Trial to enroll up to ~ 140 patients (NCT03260023)
Randomized
(1:1) Arm A
Patients with TG4001 + avelumab
Patients with
HPV16+ Anogenital Cancer recurrent/metastatic disease
Avelumab single agent
Arm B
PRIMARY ENDPOINTS SECONDARY ENDPOINTS Interim analysis data expected
Overall Response Rate around the end of 2022
Progression-Free Survival
(RECIST 1.1) Disease Control Rate (~50 patients enrolled)
Overall Survival
Other immunological parameters
Collaboration
with
17A Methodologically Sound Phase II Trial to Further Validate the Potential of TG4001
Click to edit Master title style
First patient enrolled
in June 2021
Interim analysis data
expected around the
Trial received regulatory clearance end of 2022
in the US, France and Spain
Positive interim analysis data to be
leveraged:
to discuss best way forward to
registration with health authorities
for partnering opportunities
TG4001 has potential to address all HPV positive cancers
18Our Unique Invir.IO™ Platform Rapidly Generating Multiple Virus-Powered Off-the-Shelf Drug Candidates
Invir.IO™ Patented Virus Backbone Based on Vaccinia Virus Copenhagen Strain
KeytotoeditTransformative
Click Master title style therapies
Tumor-specific replication Safe in a Targeted and Broad spectrum infectivity
Accentuated with TK-RR- double deletion large variety Continuous Can infect all types of tumor cells
Cytoplasm-restricted viral replication of routes, Delivery Potent Large and stable genome
No risk of integration into host DNA including IV Payloads High payload potential
Good tolerance in IV demonstrated from
ongoing TG6002 trials
Low-grade adverse events
Proof of Concept
of the functionality of the
intravenous administration
in human
Short time to clinic from product In-house Multiple mode of action
design to clinic (i.e. 18-24 mo) GMP Tumor · Oncolysis
manufacturing Eradication · Immune mechanisms
including mets · Therapeutic payloads
Abscopal activity demonstrated
in preclinical models for BT-001
Ongoing collaboration 20TG6002 | Chemotherapy Produced Directly in the Tumor
Interim
Click to editPhase I data
Master title style (IV*) presented at AACR 2021
The right virus PoC clinical data for IV
+ payload administration
2 ongoing Phase I/II trials evaluating IV* and
Oncolytic armed with FCU1 gene, IHA** administration
prodrug activator After IV infusion, TG6002 was detected in the
Converts 5-FC into 5-FU, a potent tumor and induced the production of 5-FU –
chemotherapy agent no major SAE (Phase I interim results)
First IV trial clinical data presented
at AACR 2021 (April 2021)
The right indication The right
5-FU sensitive cancers patient population
Colorectal cancer with liver metastases
Current SoC in 2L: bevacizumab + folfiri/folfox
(3L: regorafenib, TAS-102)
OS: ~13 months
2L: 180,000 pts/year
– EU 28 & US 21
* IV: intravenous administration **IHA: intrahepatic artery administrationTG6002 | Interim Phase I Data Presented at AACR 2021
Clinical PoC
Click to edit of title
Master feasibility of IV route for our patented VVcop TK-RR- virus
thestyle
TG6002 replicates in tumor 5-FU is expressed in tumor Long-lasting expression
tissue without sign of tissue in most of the of 5-FU
widespread replication evaluable patients (3 cohorts)
5-FU (•) and 5-FC (•) quantification
Fraction of tumor tissue positive for Correlation between plasma in plasma (1·109 pfu dose cohort)
TG6002 by qPCR or plaque assay* and tumor 5-FU at day 5
10000
TG6002 infusion 5-FC administration
60
1/2
Plasma 5-FU (ng/ml)
1000
3/8
positive tumors
1/3
% of TG6002
40
100
Patient with direct
20
10 evidence of TG6002 in
tumor are red dots ( )
0 1
3108 pfu 1109 pfu 3109 pfu 1 10 100 1000 10000
Dose cohorts
Tumor 5-FU (pg/mg)
* Sensitivity of qPCR of plaque assay is impacted by scarcity of viable cells in Days
tumor biopsies
Source: Bendjama et al. “Oncolytic virus TG6002 locates to tumors after intravenous infusion and
induces tumor-specific expression of a functional pro-drug activating enzyme in patients with advanced 22
gastrointestinal carcinomas” 2021 AACR Annual Meeting, April 9-14, 2021, Poster presentationBT-001 | Oncolytic Virus Encoding for an Anti-CTLA4 Antibody (Ab)
Click to edit Master title style
Transgene’s patented BioInvent’s potent
Invir.IO™ backbone anti-CTLA4 Ab
· Oncolysis BT-001
is designed to achieve: · Activates and increases T-effector cells
· Anti-tumor immune induction
· Treg depleting activity
· Safe delivery of payload
Strong and sustained anti-tumor Selected
activity publications:
Kleinpeter et al., 2016
Better safety vs anti-CTLA4 IV
Immune change in tumor Vargas F. et al., 2018
microenvironment
Can be developed for
multiple cancer GM-CSF Marchand et al., 2018
cytokine
indications
Stimulates immune cells (incl. APC) Semmrich et al., 2020
collaboration 23
50/50 with BioInventBT-001 | Phase I/II Trial Starting in Europe
Leverage the IT*
Click to edit Master title route
style to accelerate development with anti-PD1 (NCT04725331)
Patients with
metastatic or
Repeated and advanced
ascending doses injectable solid
Trial authorized of BT-001 IT* tumors such as:
in Europe and in the US soft tissue sarcoma,
First patient enrolled in Feb. 2021 Merkel cell
carcinoma,
melanoma, triple
neg breast cancer,
non-small cell lung
cancer
First Phase I data
to be presented in 1H 2022
(safety and translational data) Repeated doses Repeated doses
of BT-001 IT + of BT-001 IT +
pembrolizumab IV** pembrolizumab IV**
24
*IT: intratumoral administration **IV: intravenous administrationInvir.IO™ Pipeline Will Allow us to Generate Significant Value
Next
Click tocandidates
edit Master titleare
stylealready in preclinical development
Patented Potential to Optimize
backbone generate multiple Invir.IO™ value
Highly productive creation
demonstrated: novel
platform via a combination
immunotherapies Several candidates of early out-
with multiple modes in preclinical
Ability to safely be licensing and
of action against development
administered IV in-house clinical
established or novel
development
Express its payload targets
until POC
in the tumor,
including with IV
administration
25Outlook
26Company Funded to Deliver Multiple Value Generating Milestones
€19.1 million in cash and cash equivalents
at March 31, 2021 Ownership
As of June 24, 2021
€34.1 million raised in June 2021
through a private placement
In addition, Transgene holds: 62%
Tasly BioPharmaceuticals shares valued at €32.3 million Free float
38%
at the end of December 2020
• Listed on Euronext Paris
FINANCIAL VISIBILITY until 4Q 2023 • ISIN: FR0005175080 - Ticker: TNG
27Our Vision and Environmental, Social and Governance Policy
Maintain Company’s
Click to edit Master title style Sustainability by Creating Value, Strengthening Social Contribution and
Minimizing Environmental Impact
Transgene’s ESG strategy is 16 interns
based on six commitments
1,883 h 85%
permanent
4 PhD students
dedicated to work contract 11 apprentices
to patients occupational training
to our partners
to our employees
to our shareholders and investors 100%
to society and territories 91/100 of employee
evaluations include
ESG criterion
Professional
to the planet Equality Index
Gaïa EthiFinance: 63/100 (+9 pts) Our ESG policy is detailed in the Universal Registration URD
Vigeo Eiris: 44/100 (+20 pts) Document 2020, chapter 4. 2020 28
➔ Above industry benchmark2021-2022 Milestones
AClick to editLeader
World Master title style
in Virus-Powered Immunotherapies against Solid Tumors
TG4001
MVA personalised neo-antigen HPV-positive cancers therapeutic VVcopTK-RR- multi-armed oncolytic
therapeutic cancer vaccines vaccine viruses
TG4050 TG4001 TG6002 Phase I data (IHA) | 2H 2021
First data from two on-going clinical Interim analysis data | around the
trials - ovarian and head and neck end of 2022 BT-001 Initial Phase I data | 1H 2022
cancer | 4Q 2021 AstraZeneca Potential option exercise
TARGET: sign licensing agreements based on upcoming trial results
29Investment Highlights
Click to edit Master title style
Unique virus
A world leader Clinical-stage powered World-class
in virus powered immunotherapy technologies scientific and clinical
immunotherapies company to specifically target collaborations
cancer cells
myvac® and
Biological and Invir.IO™: best- Multiple key Potentially
clinical evidence in-class platforms milestones
of anti-tumor potential to expected in 2021
game
efficacy generate multiple and 2022 changer
candidates
of the
treatment
of solid tumors
30Thank you
for your attention
31Appendices
32TG4050 Process for Individualized Neoantigen Vaccination
Combines bioengineering
Click to edit Master title style and digital transformation
ROUTINE DATA PROCESSING, GENE EDITING,
TUMOR BIOPSY GENE SEQUENCING ARTIFICIAL INTELLIGENCE MANUFACTURING
Patient Next Selection of Vaccine
Treatment generation 30 neoantigens generation and
administration sequencing manufacturing
Database Epitope Scoring NEC’S NEOANTIGEN PREDICTION
Sequencing
data HLA Binding
Epitope Ranking
WXS Proprietary Database
Normal
Tumor presentation
RNA
Immunogenicity
Candidate Generation
Overall Ranking Vaccine
HLA Typing Self-Similarity
by recipe
WXS Graph-based
Tumor
RNA Expression
relational learning
Variant Calling
RNA
33TG4001 | Treatment Induced Long-Lasting Responses and Changes
in
Clickthe Tumor
to edit Master titleMicro-Environment
style
Evolution of tumor size
in patients without liver metastases TG4001 elicits strong, long-lasting and specific T-cell
response against HPV16 E6 and E7
Treatment shifts « cold » tumor into « hot » tumor
Increased CD3+ and CD8+ infiltrate
Higher PD-L1 expression
Expression of several genes
associated with activation
of the immune system Source: Le Tourneau et al.
“TG4001 (Tipapkinogene
sovacivec) and avelumab for
recurrent/metastatic (R/M)
Human Papilloma Virus (HPV)-
16+ cancers: clinical efficacy and
immunogenicity.” 2020 SITC
Annual Meeting, 9-11
November 2020, Poster
presentation
34Significant Opportunity for TG4001 in Anogenital HPV16-Positive Cancers
HPV16 etiology
Click to edit creates
Master title style a significant market opportunity
Incidence of anogenital HPV16 positive cancers
w/o liver metastases
Newly diagnosed patients with metastatic disease
and patients with recurrent disease
Clinical outcome
Vulval Cervix
8% 50% needs to be improved
~ 25,000
new patients
per year Vaginal Current treatments, mostly radio/chemotherapy,
15% do not address the etiology (viral origin) of the disease
Penile No IO drugs (ICIs) approved yet in 1L of treatment
2%
Anal Pembrolizumab approved in 2L cervix cancer (USA)
25%
65% 35%
EU27 + UK USA
Estimated cancer cases (2025) based on: 1. ICO/IARC – HPV Information Center> Prevention at a glance // 2. HPV-positive cervical cancer: Globocan/IARC 2020 Cancer Fact Sheets: cervix uteri (C53); ICO/IARC – HPV Information Center Statistics // 3. HPV-
positive vaginal cancer: Globocan/IARC 2020 Cancer Fact Sheets: vagina (C52); ICO/IARC – HPV Information Center Statistics // 4. HPV-positive vulvar cancer: Globocan/IARC 2020 Cancer Fact Sheets: vulva (C51); ICO/IARC – HPV Information Center Statistics; CDC
United States Cancer Statistics: Data Visualizations; SEER Cancer stat facts: vulvar cancer // 5. HPV-positive anal cancer: Globocan/IARC 2020 Cancer Fact Sheets: anus (C21); ICO/IARC – HPV Information Center Statistics; CDC>Cancer Home>HPV and
Cancer>Statistics>Rates by Race and Ethnicity>HPV-Associated Anal Cancer Rates by Race and Ethnicity; American Cancer Society: Anal Cancer // 6. HPV-positive penile cancer: Globocan/IARC 2020 Cancer Fact Sheets: penis (C60); ICO/IARC – HPV Information
35
Center Statistics; CDC>Cancer Home>HPV and Cancer>Statistics>Rates by Race and Ethnicity>HPV-Associated Cancers Rates by Race and EthnicityMultiple Payloads | Deliver Significant Patient Benefits
Local
Click to payload
edit Master delivery
title style helps better neutralize the tumor in an effective and safe manner by
limiting systemic exposure
Targeted insertion of recombinant payload
at selected loci in the Vaccinia genome
Several
IMMUNE MODULATORS PRODRUG payloads can be
ACTIVATORS encoded in one
ICIs (e.g. PD-1/PD-L1, multi-armed OV
CTLA4, TIM-3, …) e.g. Fcu1 (TG6002), an (several loci, up to 20-
Monoclonal antibodies enzyme that locally 25 kb capacity)
or fragments converts 5-FC into 5-FU,
(scFV, Fab, …) a chemotherapeutic
agent
Enzymes controlling Multiple
immunosuppressive payload
metabolites (e.g. ADA) sourcing
IMMUNE BOOSTERS
approaches
Cytokine (e.g. GM-CSF, interleukins, … )
Agonistic ligands (e.g. CD40L, Flt3L, …)
Growth Factors (e.g. VEGF)
36Ongoing Collaboration with AstraZeneca (AZ)
Invir.IO™ platform
Click to edit Master validation
title style
AstraZeneca 5 novel
secured an therapeutic Of 5 novel oncolytic
payloads to be immunotherapies, Possible option
access to
integrated in our 2 have been exercise by AZ
Transgene’s
VVCOPTK-RR- on each candidate
Invir.IO™ delivered to AZ
proprietary
platform backbone
Looking to augment To continue
in-house expertise development
in OVs in the clinic
Transgene
in charge of GMP
manufacturing
Could generate additional revenues for Transgene of clinical batches
and further validate Invir.IO™ in the clinic
37TG6002 | Two Phase I/IIa trials in 5-FU sensitive GI indications
Two
Click tonovel administration
edit Master title style routes - IV and IHA
Gastro-intestinal adenocarcinoma with liver Colorectal cancer patients with unresectable
metastasis (colon cancer) - TG6002 IV + oral 5-FC liver metastases (CRLM) – TG6002 IHA + oral 5-FC
Interim data
Phase I (dose escalation) demonstrate 5-FU Phase I (dose escalation)
up to 40 patients production in the up to 30 patients
tumor - no major SAE
PoC data
presented
Phase IIa part (efficacy) at AACR 2021 Phase IIa part (efficacy)
35 patients 38 patients
PRINCIPAL INVESTIGATOR: Prof Philippe Cassier, PRINCIPAL INVESTIGATOR: Dr. Adel Samson,
centre Léon Bérard (Lyon, France) St. James’ University Hospital (Leeds, UK)
INDs granted in Belgium, Spain, France IND granted in the UK, France
38BT-001 | Exciting Preclinical Data
Click to edit Master title style
Strong abscopal effect
(impact on distant lesions)
i.t. injection
CT26
Semmrich et al., BT-001, an
oncolytic vaccinia virus armed
with a Treg-depleting human
recombinant anti-CTLA4
antibody and GM-CSF to target
the tumor microenvironment,
SITC, Nov. 2020
39
39C O N TA C T
Lucie Larguier
Director Investor Relations
and Corporate Communication
+33 6 7624 7227
larguier@transgene.fr
400 Boulevard Gonthier d’Andernach | Parc d’Innovation | CS80166
67405 Illkirch Graffenstaden Cedex | France
Tél.: + 33 (0)3 88 27 91 21 | www.transgene.frYou can also read
